The Food and Drug Administration has selected UCSF as the site of a new regulatory science center on the West Coast. The center aims to spur innovative approaches in drug development that will support the FDA’s ability to evaluate and approve safe and effective new medications.
April 21, 2014
Despite its potentially harmful effects in children, codeine continues to be prescribed in U.S. emergency rooms, according to new research from UCSF Benioff Children’s Hospital San Francisco.
January 24, 2014
A new analysis of animal studies on cholesterol-lowering statins by UC San Francisco researchers found that non-industry studies had results that favored the drugs even more than studies funded by industry.
November 20, 2013
The protein in cells that most often drives the development of cancers has eluded scientists’ efforts to block it for three decades — until now.
July 18, 2013
UCSF researchers have found a way to knock down cancers caused by a tumor-driving protein called “myc,” paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.
June 18, 2013
Aspirin is known to lower risk for some cancers, and a new UCSF-led study points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells in at least one pre-cancerous condition.
April 29, 2013
Some of the most widely prescribed antidepressant medications are associated with increased risk of bleeding, transfusion, hospital readmission and death when taken around the time of surgery, according to an analysis co-led by UCSF.
March 22, 2013
The Li Ka Shing Foundation has pledged $2 million to support UCSF’s efforts to advance precision medicine, an emerging field aimed at revolutionizing medical research and patient care.
December 17, 2012
Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.
July 01, 2012
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.